Erdafitinib 3mg Tablets

Erdafitinib 3mg is a targeted anticancer medicine used for selected cancers with susceptible FGFR genetic alterations when erdafitinib is prescribed by an oncology specialist. It inhibits fibroblast growth factor receptors, which can drive tumor growth in some cancers such as urothelial carcinoma with qualifying alterations.
Take Erdafitinib 3mg exactly as the oncology team prescribes. Do not start unless FGFR alteration status, monitoring, and dose plan are confirmed.
Erdafitinib inhibits FGFR signalling pathways that can promote growth of tumours with susceptible FGFR alterations.
Possible effects include mouth sores, diarrhea, dry mouth, nail changes, dry skin, fatigue, high phosphate, and appetite changes. Serious concerns include retinal disorders, severe eye symptoms, embryo-fetal harm, and significant lab abnormalities.
Review FGFR test result, cancer indication, eye exams, phosphate level, kidney/liver tests, pregnancy prevention, breastfeeding avoidance, CYP interactions, phosphate binders, and visual symptoms.
Selected FGFR-altered cancers when prescribed by an oncology specialist.
Targets FGFR-driven cancer biology in biomarker-selected patients with specialist monitoring.
It is used only for selected FGFR-altered cancers when an oncology specialist confirms that the indication and monitoring plan fit.
Take Erdafitinib 3mg exactly as the oncology team prescribes. Do not start unless FGFR alteration status, monitoring, and dose plan are confirmed.
Tell your doctor about FGFR test result, cancer indication, eye exams, phosphate level, kidney/liver tests, pregnancy prevention, breastfeeding avoidance, CYP interactions, phosphate binders, and visual symptoms.
Side effects can include mouth sores, diarrhea, dry mouth, nail changes, dry skin, fatigue, high phosphate, and appetite changes. Seek urgent medical advice for retinal disorders, severe eye symptoms, embryo-fetal harm, and significant lab abnormalities.
Erdafitinib, FGFR inhibitor, Targeted cancer therapy, Urothelial carcinoma, Phosphate monitoring, Retinal toxicity warning, AR: Erdafitinib أقراص, FR: Erdafitinib comprimé, PT: Erdafitinib comprimido, ES: Erdafitinib tableta, RU: Erdafitinib таблетки, ID: Erdafitinib, VI: Erdafitinib viên nén, MS: Erdafitinib, TL: Erdafitinib tableta, ZH-SG: Erdafitinib 片剂
International B2B Enquiry
Send a structured B2B enquiry for Erdafitinib 3mg Tablets under Oncology Care. Global Medicines Export helps international buyers review product information, pack details, quantity requirements, destination-market needs, quotation support and export documentation coordination from India.
Product name, required strength or pack, expected quantity, destination country, buyer type and preferred manufacturer if any.
Availability, quotation support, documentation expectations and shipment-ready order communication can be reviewed before confirmation.
Commercial invoice, packing information, manufacturer details, batch details and supporting documents where applicable and available.
Product availability, quotation, and documentation support are coordinated for international B2B enquiries.
Erdafitinib 3mg Tablets